Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
LMAN1 serves as a cargo receptor for thrombopoietin
Lesley A. Everett, Zesen Lin, Ann Friedman, Vi T. Tang, Greggory Myers, Ginette Balbin-Cuesta, Richard King, Guojing Zhu, Beth McGee, Rami Khoriaty
Lesley A. Everett, Zesen Lin, Ann Friedman, Vi T. Tang, Greggory Myers, Ginette Balbin-Cuesta, Richard King, Guojing Zhu, Beth McGee, Rami Khoriaty
View: Text | PDF
Research Article Hematology

LMAN1 serves as a cargo receptor for thrombopoietin

  • Text
  • PDF
Abstract

Thrombopoietin (TPO) is a plasma glycoprotein that binds its receptor on megakaryocytes (MKs) and MK progenitors, resulting in enhanced platelet production. The mechanism by which TPO is secreted from hepatocytes remains poorly understood. Lectin mannose-binding 1 (LMAN1) and multiple coagulation factor deficiency 2 (MCFD2) form a complex at the endoplasmic reticulum membrane, recruiting cargo proteins into COPII vesicles for secretion. In this study, we showed that LMAN1-deficient mice (with complete germline LMAN1 deficiency) exhibited mild thrombocytopenia, whereas the platelet count was entirely normal in mice with approximately 7% Lman1 expression. Surprisingly, mice deleted for Mcfd2 did not exhibit thrombocytopenia. Analysis of peripheral blood from LMAN1-deficient mice demonstrated normal platelet size and normal morphology of dense and alpha granules. LMAN1-deficient mice exhibited a trend toward reduced MK and MK progenitors in the bone marrow. We next showed that hepatocyte-specific but not hematopoietic Lman1 deletion results in thrombocytopenia, with plasma TPO level reduced in LMAN1-deficient mice, despite normal Tpo mRNA levels in LMAN1-deficient livers. TPO and LMAN1 interacted by coimmunoprecipitation in a heterologous cell line, and TPO accumulated intracellularly in LMAN1-deleted cells. Together, these studies verified the hepatocyte as the cell of origin for TPO production in vivo and were consistent with LMAN1 as the endoplasmic reticulum cargo receptor that mediates the efficient secretion of TPO. To our knowledge, TPO is the first example of an LMAN1-dependent cargo that is independent of MCFD2.

Authors

Lesley A. Everett, Zesen Lin, Ann Friedman, Vi T. Tang, Greggory Myers, Ginette Balbin-Cuesta, Richard King, Guojing Zhu, Beth McGee, Rami Khoriaty

×

Figure 5

LMAN1 mediates the efficient secretion of TPO.

Options: View larger image (or click on image) Download as PowerPoint
LMAN1 mediates the efficient secretion of TPO.
(A) Plasma TPO level is r...
(A) Plasma TPO level is reduced in LMAN1-deficient compared with WT littermate control mice. (B) Tpo mRNA levels were indistinguishable between Lman1–/– and WT control mice, as demonstrated using 3 different Tpo primer sets. (C) FLAG-tagged LMAN1 (LMAN1-FLAG) and myc-tagged TPO (TPO-myc) were expressed in HEK293T cells. A physical interaction between TPO and LMAN1 was suggested, as an anti-FLAG antibody coimmunoprecipitated TPO-myc. In, input (10%); IP, immunoprecipitated fraction. (D and E) A reporter human HEK293T cell line that expresses EGFP-fused TPO and mCherry-fused A1AT was generated. (D) Deletion of LMAN1 using an LMAN1-targeting sgRNA resulted in intracellular accumulation of TPO and A1AT compared with cells transduced with a nontargeting (NT) sgRNA. (E) Immunofluorescence microscopy demonstrates significantly increased colocalization of TPO in the ER (labeled with blue fluorescent protein) in cells transfected with LMAN1-targeting sgRNA (LMAN1 KO) compared with control cells (WT). ****P < 0.0001. PCC, Pearson correlation coefficient. (F) A reporter cell line expressing TPO fused to mCherry and PCSK9 fused to EGFP was generated. LMAN1 deletion results in intracellular accumulation of TPO but not PCSK9. (G) LMAN1 deletion (LMAN1 KO) in HEP3B cells treated with 80 ng/mL IL-6 results in reduced TPO in the supernatant compared with control cells transduced with nontargeting (NT) sgRNA. ***P < 0.001. Statistical analyses in this figure were performed using unpaired Student’s t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts